Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Akebia surges after positive results in Phase 3 studies of kidney disease-related anemia

% of readers think this story is Fact. Add your two cents.


Akebia Therapeutics Inc (NASDAQ:AKBA) surged Tuesday after reporting positive results from a pair of Phase 3 studies on the treatment of anemia related to chronic kidney disease.

The studies of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, were conducted by its commercialization collaboration partner in JapanMitsubishi Tanabe Pharma Corp.

Shares of Akebia rallied 25% to $9.19 in Tuesday’s premarket Nasdaq trading.

READ: Feraccru a potential game changer in the treatment of iron deficiency anaemia

Each study, one in non-dialysis dependent subjects and one in hemodialysis-dependent subjects, met its primary endpoint, according to Akebia. In addition, results from two Phase 3 single-arm studies conducted by Mitsubishi Tanabe, further supported vadadustat’s potential, according to Cambridge, Massachusetts-based Akebia.

Mitsubishi Tanabe expects to submit a new drug application in 2019 in Japan.

“These data provide further confirmation of vadadustat’s potential to meaningfully transform the treatment paradigm for patients with anemia due to chronic kidney disease,” Akebia CEO  John P. Butler said in a statement. “These results add to our data set demonstrating the potential for vadadustat to effectively manage hemoglobin levels in both dialysis-dependent and non-dialysis-dependent patients.”

Phase 3 outcomes

A phase 3 randomized, open-label, active-controlled correction and conversion study for non-dialysis dependent subjects met its primary endpoint, with the mean hemoglobin level at week 20 and week 24 at 11.66 grams per deciliter for vadadustat-treated subjects, compared with 11.93 for other subjects. Another Phase 3 study of hemodialysis subjects also met its primary endpoint, with the mean hemoglobin level at week 20 and week 24 at 10.61 grams per deciliter, compared with 10.65 for other subjects.

Anemia is common in patients with chronic kidney disease, and in Japan, an estimated 13 million people are afflicted with advanced stages of chronic kidney disease, according to Akebia.

Vadadustat, if approved for marketing, would provide patients with a once-daily oral treatment option and has the potential to set a new standard of care, the company said.

Contact Dennis Fitzgerald at [email protected]

Story by ProactiveInvestors


Source: https://www.proactiveinvestors.com/companies/news/216298/akebia-surges-after-positive-results-in-phase-3-studies-of-kidney-disease-related-anemia-216298.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)

Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen!

Nascent Iodine - Promotes detoxification, mental focus and thyroid health.

Smart Meter Cover -  Reduces Smart Meter radiation by 96%! (See Video).

Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.